

28th-29th November, 2018
Basel Congress Center

Host Partners:



- **Bertrand Bodson**, Chief Digital Officer, **Novartis**
- **Rob Scott**, Chief Medical Officer, **AbbVie**
- **Sue Hill**, Chief Scientific Officer, **NHS England**
- **Abel Archundia**, Global Head of IT, **Bayer**
- **Philippe Marc**, Global Head of Integrated Data Sciences, **Novartis Institutes for BioMedical Research (NIBR)**
- **Diego Ardigo**, Global Head of Rare Diseases, **Chiesi**
- **Vikram Bajaj**, Managing Director, **Forsite Capital Management**, Former CSO **Grail**, Co-Founder, **Verily (Google Life Sciences)**
- **Menelas Pangalos**, Executive Vice President of Innovative Medicines and Early Development Biotech Unit and Global Business Development, **AstraZeneca**
- **Achim Plueckebaum**, Global Head Development IT, **Novartis**
- **Etzard Stolte**, Global Head of Knowledge Management PTD, **Roche**
- **Jean Claude Zenklusen**, Director, The Cancer Genome Atlas, **National Cancer Institute**, **National Institutes of Health**
- **Joachim Luithle**, Head of Clinical Development Operations, **Bayer**
- **Steve Guise**, Global Head, Pharma Informatics, **Roche**
- **Ian Pepper**, CTO/Head of Strategy and Integration Architecture, **Novartis**
- **Jasmin Saric**, Head of Digital Ideation and Scouting, **Boehringer Ingelheim**

28th-29th November, 2018

Basel Congress Center

- **Frank Bretz**, Global Head of Statistical Methodology, **Novartis**
- **Steffen Roellinger**, SVP - Head Portfolio & Operations, Pharma R&D, **Bayer**
- **Peter Speyer**, Global Head of Real World Evidence Solutions, **Novartis**
- **Tim Cave**, VP, Medical Affairs Strategic Planning & Digital Practices, **GSK**
- **Tim Stitt**, Principal Architect for HPC Strategy and Architecture, **Roche**
- **Zheng Yang**, Global Head of Technology and Data Innovation, Customer Value, **Boehringer Ingelheim**
- **Nicola Orlandi**, Head Data Privacy Pharma, **Novartis International**
- **Athula Herath**, Global Head of Real World Evidence Epidemiology, **Novartis**
- **Michel Van Speybroeck**, Director Data Sciences, **Janssen**
- **David Fenstermacher**, Vice President R&D Bioinformatics, **MedImmune**
- **Chris Boone**, Vice President, Real World Data and Analytics, **Pfizer**
- **Stanley Lazic**, Associate Director, Statistics and Machine Learning, **AstraZeneca**
- **Mats Sundgren**, Director Health Informatics, **AstraZeneca**
- **Dirk Voelkel**, Chief Technology Officer, **GE Healthcare**
- **Nigel Hughes**, Scientific Director, Janssen Clinical Innovation, **Janssen**
- **Mark Baillie**, Associate Director, Statistical methodology and consulting, **Novartis**
- **Derek Marren**, Director - Research IT - Biology systems & Data Integration, **Eli Lilly**
- **Slavé Petrovski**, VP and Head of Genome Analytics, **AstraZeneca**
- **Ravi Kiron**, Head, BioPharma External Innovation, **EMD Serono**
- **Sandy Farmer**, Executive Director, Genome Sciences & Technologies, **Pfizer**
- **Govinda Rao Bhisetti**, Principal Investigator and Head of Computational Chemistry, **Biogen**
- **Alexander Krupp**, Head of Computational Life Science IT Pharmaceuticals, **Bayer**
- **Sherry Cao**, Group Head, Scientific IT Informatics, **AbbVie**
- **Sandor Szalma**, Senior Director, Biomedical Informatics, **Takeda Pharmaceuticals**
- **Matthew Nelson**, Head of Genetics, **GSK**

28th-29th November, 2018
Basel Congress Center

- **Shanrong Zhao**, Director, Computational Biology and Bioinformatics, **Pfizer Worldwide Research & Development**
- **Philippe Sanseau**, Head Computational Biology and Stats, **GSK**
- **Lucie Eckenberg-Friedlander**, Translational Medicine Data Governance Leader, **Sanofi**
- **Darryl Davis**, Head of Biophysical Research & Analytics, **Janssen**
- **Marco Prunotto**, Senior Clinical Development Scientist at Roche & Genentech (Late stage), **Roche**
- **Jan Kuentzer**, Head of Data Science Application Services, **Roche**
- **Riccardo Sabatini**, Co-Founder, Chief Data Officer, **Orion Biosciences**
- **Sonali Quantius**, Director, Computational Biology, **GSK**
- **William Paiva**, Executive Director, Center for Health Systems Innovation, **Oklahoma State University**
- **Suleiman Khan**, Senior Researcher, **Institute for Molecular Medicine Finland**
- **Bhupinder Bhullar**, Project Manager, **Baselarea**
- **Redouane Boumghar**, Research Fellow - Data Intelligence & Robotics, **European Space Agency**
- **Pedro Ballester**, Research Group Leader, **INSERM**
- **David Smith**, Professor of Laboratory Medicine and Pathology, **Mayo Clinic**
- **Matthieu-P. Schapranow**, Program Manager E-Health, **Hasso Plattner Institute**
- **Torsten Schwede**, Director of Data Coordination Centre of the Swiss Personalized Health Network, **Swiss Institute of Bioinformatics**
- **Jennifer Hall**, Chief, The Institute for Precision Cardiovascular Medicine, **American Heart Association**,
- **Ioannis Xenarios**, Director, Swiss-Prot/Vital-IT Group, **Swiss Institute of Bioinformatics**
- **Rolf Apweiler**, Director, **EMBL-EBI**
- **Mimi Choon-Quinones**, Executive Senior Director, Clinical Operations and Patient Engagement, **Arena Pharmaceuticals**
- **Ben Maruthappu**, Co-founder, NHS Innovation Accelerator, **NHS Innovation Accelerator**
- **Shameer Khader**, Program Director (Healthcare Data Science and Bioinformatics), **Northwell Health**
- **Anna Berry**, Scientific Director of Personalized Medicine and Medical Director of Molecular Diagnostics, **Swedish Cancer Institute and Cellnetix**
- **Olivier Elemento**, Director, **Englander Institute for Precision Medicine**
- **Serena Scollen**, Head of Human Genomics and Translational Data, **ELIXIR**

28th-29th November, 2018

Basel Congress Center

- **Mathew Pletcher**, Head of Rare Diseases, **Roche**
- **Zdenko Herceg**, Head, Section of Mechanisms of Carcinogenesis, **WHO**
- **Indra Joshi**, Head Digital Health and AI Clinical Lead, **NHS**
- **Polina Mamoshina**, Research Scientist, **Pharma.AI**
- **Steven Hart**, Associate Director of Bioinformatics, Clinical Genome Sequencing Laboratory (CGSL), **Mayo Clinic**
- **Olivier Leconte**, Data Operation Development Units, Global Head, **Novartis**
- **Alain Bindels**, Innovation task force Leader, **Roche**
- **Kate Merton**, Head, JLABS NYC & Boston, **Johnson & Johnson**
- **Catherine Brownstein**, Scientific Director, **Manton Center for Orphan Disease Research**, **Boston Children's Hospital**, **Harvard Medical School**
- **Matt Brauer**, Director of Data Science & Statistical Computing; Senior Scientist, **Genentech**
- **Slava Akmaev**, Vice President and Chief Analytics Officer, **BERG Health**
- **Martin Erkens**, Head of Pharma Research and Early Development Informatics, **Roche**
- **Ralph Haffner**, Global Area Head - Research Informatics, **Roche**
- **Oliver Gassner**, Head Digital Health Intelligence | EMEA, **Bayer**
- **Jacqueline Law**, Vice President, Global Head, PHC Data Science, Personalized Healthcare, Product Development, **Genentech**
- **Joerg Degen**, Project Leader, Pharma Research and Early Development Informatics, **Roche**
- **Ben Sidders**, Team Leader, Oncology Bioinformatics, **AstraZeneca**
- **Michelle Krishnan**, Translational Medicine Leader in Rare, Diseases, **Roche**
- **Simeen Malik**, Sr. Bioinformatics Scientist, **MSD**
- **Christof Von Kalle**, Director, Division of Translational Oncology, **N.C.T. and D.K.F.Z.**
- **Jobst Loeffler**, Project Manager, Bayer Business Services GmbH, IT Operations, Scientific Development IT, **Bayer**
- **David Whewell**, Director of Architecture and Software Innovation, **Merck Group**
- **Achim Kless**, Scientific Director, **Grunenthal**
- **Ian Barrett**, Associate Director, Quantitative Biology, **AstraZeneca**

28th-29th November, 2018

Basel Congress Center

- **Eike Staub**, Head of Oncology Bioinformatics Biopharma | R&D Global Early Development, **Merck KGaA**
- **Dónal Landers**, Director - digital Experimental Cancer Medicine Team, **CRUK Manchester Institute/The Christie**, Senior Director Physician, **AstraZeneca**
- **Anusha Sridharan**, Lead, Health Information Technology, Data, and Partnerships (Office of CIO), **Merck**
- **Tapan Mehta**, Head, Global Healthcare & Life Sciences Marketing, **Nutanix**
- **Gabriel Eichler**, Data & Analytics Workstream Lead - Kraft Precision Medicine Accelerator, **Harvard Business School**
- **Michael Rebhan**, Senior Investigator, **Novartis**
- **Quin Wills**, Head of Advanced Genomics, **Novo Nordisk**
- **Justin Lecher**, Scientific Computing/Cloud Computing/HPC Architect, **AstraZeneca**
- **Jan Nygaard Jensen**, Scientific Director, Head of Bioinformatics Discovery, **Novo Nordisk**
- **Mark Sluijs**, Digital Investment Advisory, **Merck**
- **Eunice Jung**, Associate Director of Value Based Medicine, **Biogen**
- **Maria Chiara Atzori**, Head of Data Privacy Switzerland, **Novartis**
- **Florian Hahne**, Senior Investigator, **Novartis**
- **Gary Saunders**, Human Data Coordinator, **EMBL-EBI**
- **Roberto Iacone**, CSO/VP, **Bright Peak**, Former head of Rare Diseases, **Roche**
- **Michael Scharfe**, Data Architect, **Novartis**
- **Vibhor Gupta**, Entrepreneur in residence, **Nextgen Capital Ventures**
- **Moritz Gilsdorf**, Senior Scientific Software Engineer, **Roche**
- **Marc Ansari**, Director of the Research Laboratory in Hematology and Oncology Pediatric, **Hôpital Universitaire de Genève**
- **Nicholas Kelley**, Research Investigator, Informatics Solutions, **Novartis**
- **Ramzi Temanni**, Technical Manager – Bioinformatics, **SIDRA Medicine**
- **Olivier Roche**, Global Data Quality Coordinator, Biology Workflow Team Leader, **Roche**
- **Lena Hansson**, Principal Scientist, **Novo Nordisk**
- **Enrique Toledo**, Senior Scientist, **Novo Nordisk**

28th-29th November, 2018
Basel Congress Center

- **Andrew Lowe**, Senior Scientist, **Novo Nordisk**
- **Vibhor Gupta**, Director and Founder, **Pangea Data**
- **Jennifer Cham**, Lead User Experience Designer, **EMBL-EBI**
- **Ron Chen**, Head of Informatics Asia Pacific and Merck R&D China IT, **MSD**
- **Mark Fingerhuth**, Founder & CEO, **ProteinQure Inc**
- **Thomas Clozel**, Founder & CEO, **Owkin**
- **Tom Stubbs**, CEO, **Chronomics**
- **Enrico Ferrero**, Senior Investigator I, **Novartis**
- **Sidekick Health- Reserved**
- **Vadim Shpak**, Managing Director, **Vickers Venture Partners**
- **Greg Lefebvre**, Genomic Data Science Team Lead, **Nestle Institute of Health Sciences**
- **Dmitry Kaminskiy**, Co-founder, Senior Partner, **Deep Knowledge Ventures**
- **Karen Keely**, Partner, **RARE Sciences**
- **Freddy Abnoui**, Head of Healthcare, **Facebook**
- **Roberto Iacone**, CSO/VP, **Bright Peak**
- **Jerome Carayol**, Data Analyst, **Nestle Institute of Health Sciences**
- **Andrew LeBeau**, Senior Manager, Biologics Marketing, **Dotmatics**
- **Neel Madhukar**, Runway Startup Postdoc Forbes 30Under30 (Healthcare), Runway Startup Postdoc, **Weill Cornell Medicine**
- **Andrew Bate**, Senior Director, Analytics Team Lead, Epidemiology, **Pfizer**
- **John Batchelor**, Senior Outcomes Measurement Scientist, **Roche**
- **Florian Lipsmeier**, Principal Data Scientist; pRED Informatics, **Roche**
- **Tina Woods**, CEO, **Collider Health**
- **Nastasia Georgievskaya**, General Manager, **Youth Laboratories**
- **Alexander Zhebrak**, CTO, **Insilco Medicine**
- **Kristen Fortney**, CEO, **BIOAGE**

28th-29th November, 2018

Basel Congress Center

- **Ian Dunham**, Scientific Director, Open Targets, **EMBL-EBI**
- **Dawid Nidzworski**, CTO, **SensDX**
- **Ieuan Clay**, Group Lead Digital Endpoints, **Novartis**
- **Diego Ray**, Visiting partner, **Y-Combinator**
- **Cecilia Lindskog**, Director, **Human Protein Atlas**
- **John Reynders**, Vice President, R&D Strategy, Program Management and Data Sciences, **Alexion Pharmaceuticals**
- **Sebastien Lefebvre**, Senior Director Data Analytics & Decision Support, **Alexion Pharmaceuticals**
- **Peter V. Henstock**, Senior Data Scientist: Machine Learning, Software Engineering, Statistics & Visualization, **Pfizer**
- **Raj Sasidharan**, Director of Genomics, **Solvuu**
- **Raj Dattani**, Principle, **Juvenescence**
- **Paul Strijbos**, Global Head of Digital, **Roche**
- **Robin Röhm**, CEO and Co-Founder, **Janus Genomics**
- **Tom Rush**, ATOM Chief Scientific Officer & Interim Co-Lead, Senior Director and Head of Biology Automation, **GSK**
- **Xose Fernandez**, Chief Data Officer, **Institut Curie**
- **Lena Granovsky**, Director, Analytics and Big Data, **Teva Pharmaceuticals**
- **Daniel Zahnd**, Professor, **Bern University of Applied Science**
- **Wolfgang Mertz**, CTO, **DELL EMC**
- **Mikhail Zaslavskiy**, Head of R&D, **OWKIN**
- **Scott Askin**, Digital Solutions Director, Digital Development, Portfolio, Strategy & Innovation (PS&I), **Novartis**
- **Harpreet Sood**, Chief Clinical Information Officer, **NHS England**
- **Hamish Graham**, Pfizer Healthcare Hub: London Manager, **Pfizer**
- **Dave Ficenec**, Global Head of Architecture, R&D IS/IT, **Takeda Pharmaceuticals**
- **Nicola Perrin**, Head, Data for Science & Health Priority (Development Phase), **Wellcome Trust**

28th-29th November, 2018
Basel Congress Center

- **James Thomas**, CTO, **Wellcome Trust**
- **Alison David**, CIO, **Francis Crick Institute**
- **Osh Agabi**, Founder and Chief Executive Officer, **Koniku**
- **Pierre-Mikael Legris**, CEO & Co Founder, **Pryv**
- **Evelina Georgieva**, CEO & Co-Founder, **Pryv**
- **Lars Greiffenberg**, Director Information Research, Library Sciences and Academic Partnerships, **AbbVie**
- **Dipak Kalra**, President of the **European Institute for Health Records**, President, **European Institute for Innovation through Health Data**
- **Ian Dunham**, Scientific Director, Open Targets, **EMBL-EBI**
- **David Hulcoop**, Open Targets Operations Director, **GSK**

Day 1 – Wednesday 28TH November 2018

8.30 **Registration & refreshments**

8.55 **Chair's opening remarks** (Canton of Basel-Stadt representative)

Morning Plenary

9.00 **Keynote opening address**



28th-29th November, 2018
Basel Congress Center

Abel Archundia, Global Head of IT, **Bayer**

9.20 Title Sponsor

09.40 AI- the future of medicine

Bertrand Bodson, Chief Digital Officer, **Novartis**

10:00 Enabling healthcare and precision medicine with AI

Sue Hill, Chief Scientific Officer, **NHS England**

10.20 Speed Networking

10.40 Morning refreshments

11.20 Platinum Sponsor



11:40

Roundtable 1: Biomarker discovery in the world of AI

CHAIR: Suleiman Khan, Senior Researcher, **Institute for Molecular Medicine Finland**

Roberto Iacone, CSO/VP, **Bright Peak**



Congress 2018

28th-29th November, 2018
Basel Congress Center

Michael Scharfe, Data Architect, **Novartis**

Enrico Ferrero, Senior Investigator I, **Novartis**

+

Roundtable 2: Using Electronic Medical Record (EMR) data to inform big pharma's drug discovery, development, and marketing processes

CHAIR: William Paiva, Executive Director, Center for Health Systems Innovation, **Oklahoma State University**

Nicholas Kelley, Research Investigator, Informatics Solutions, **Novartis**

+

Roundtable 3: 

+

Roundtable 4: Data Management and Democratisation

CHAIR: Olivier Leconte, Data Operation Development Units, Global Head, **Novartis**

Torsten Schwede, Director, **Data Coordination Centre of the Swiss Personalized Health Network (SPHN)**, Director, sciCORE - center for scientific computing, **University of Basel**

Moritz Gilsdorf, Senior Scientific Software Engineer, **Roche**

Olivier Roche, Global Data Quality Coordinator, Biology Workflow Team Leader, **Roche**

+

Roundtable 5:



+

Roundtable 6: Accelerating Innovation in Pharmaceuticals

CHAIR: Alain Bindels, Innovation Lab Director, **Roche**

Kate Merton, Head, JLABS NYC & Boston, **Johnson & Johnson**

Michael Rebhan, Senior Investigator, **Novartis**

28th-29th November, 2018
Basel Congress Center

Pierre-Mikael Legris, CEO & Co Founder, **Pryv**
Evelina Georgieva, CEO & Co-Founder, **Pryv**
Hamish Graham, Pfizer Healthcare Hub: London Manager, **Pfizer**

+

Lena Hansson, Principal Scientist, **Novo Nordisk**
Enrique Toledo, Senior Scientist, **Novo Nordisk**
Andrew Lowe, Senior Scientist, **Novo Nordisk**

+

Roundtable 7: Navigating Real World Data & Applied Analytics

CHAIR: Gabriel Eichler, Data & Analytics Workstream Lead - Kraft Precision Medicine Accelerator, **Harvard Business School**

+

Roundtable 8: Sequencing and collaboration

CHAIR: Quin Wills, Head of Advanced Genomics, **Novo Nordisk**

Jan Nygaard Jensen, Scientific Director, Head of Bioinformatics Discovery, **Novo Nordisk**

David Lloyd, Project Technical Coordinator, **ELIXIR**

+

Roundtable 9: Using digital technologies in clinical trials

CHAIR: Diego Ardigo, Global Head of Rare Diseases, **Chiesi**

Dirk Voelkel, CTO - Innovation & Analytics, **GE Healthcare - Life Sciences**

Florian Hahne, Senior Investigator, **Novartis**

+

Roundtable 10: Using RWD across borders

CHAIR: Eunice Jung, Associate Director of Value Based Medicine, **Biogen**

+

Roundtable 11: Examining developments on data privacy



Congress 2018

28th-29th November, 2018
Basel Congress Center

CHAIR: Nicola Orlandi, Head Data Privacy Pharma, **Novartis International**
Maria Chiara Atzori, Head of Data Privacy Switzerland, **Novartis**

+

Roundtable 12: Emerging Investment Thesis – Engaging results from large scale investments

CHAIR: Mark Sluijs, Digital Investment Advisory, **Merck**

+

Roundtable 13: Topic TBC

CHAIR: Jennifer Cham, Lead User Experience Designer, **EMBL-EBI**

+

Round table 14: Translational Oncology Informatics

Ron Chen, Head of Informatics Asia Pacific and Merck R&D China IT, **MSD**

+

Round table 15: Examining device-based data capture and analytics

Steffen Roellinger, SVP - Head Portfolio & Operations, Pharma R&D, **Bayer**

+

Round table 16: UN Round Table: Block Chain and Health Records

Karen Keely, Partner, **RARE Sciences**

Lars Greiffenberg, Director Information Research, Library Sciences and Academic Partnerships, **AbbVie**

+

Round table 17: Social determinants for healthcare

Freddy Abnoui, Head of Healthcare, **Facebook**

+

Round table 18



+

28th-29th November, 2018
Basel Congress Center

Round table 19



+

Round table 20: Sharing clinical data

Xose Fernandez, Chief Data Officer, **Institut Curie**

+

Round table 21: Title to be confirmed

James Thomas, CTO, **Wellcome Trust**

12:30 **Networking Lunch**

<u>IT, DATA MANAGEMENT AND STORAGE</u>	<u>BIOINFORMATICS</u>	<u>AI, AUTOMATION AND MACHINE LEARNING</u>	<u>BIG DATA IN ONCOLOGY</u>	<u>DATA INTEGRATION & INFRASTRUCTURE</u>
<u>TRACK 1</u>	<u>TRACK 2</u>	<u>TRACK 3</u>	<u>TRACK 4</u>	<u>TRACK 5</u>
13.30 Chair's remarks Jasmin Saric , Head of Digital Ideation and Scouting, Boehringer Ingelheim	13.30 Chair's remarks Xose Fernandez , Chief Data Officer, Institut Curie	13.30 Chair's remarks Paul Strijbos , Global Head of Digital, Roche	13.30 Chair's remarks Jean Claude Zenklusen , Director, The Cancer Genome Atlas, National Cancer Institute , National Institutes of Health	13.30 Chair's remarks Peter Speyer , Global Head of Real World Evidence Solutions, Novartis

28th-29th November, 2018

Basel Congress Center

13.35 How to make data accessible? - Pooling of internal and external data sources for clinical development - Overview on business use cases at Novartis, and underlying technology platform(s) - Critical enablers of the journey (e.g. agile governance, partner ecosystem, rapid data prototyping) Achim Plueckebaum, Global Head Development IT, Novartis	13.35 The genetics of drug efficacy: opportunities and challenges Matthew Nelson, Head of Genetics, GSK	13.35 	13.35 Getting meaning from Data: reading through the data Jean Claude Zenklusen, Director, The Cancer Genome Atlas, National Cancer Institute, National Institutes of Health	13.35 From data archiving to knowledge representation: Research infrastructure provision at EBI Rolf Apweiler, Director, EMBL-EBI
13.55 Optimizing Big Data Workloads to Accelerate Drug Development Pharmaceutical companies are saddled with legacy systems containing heterogeneous and disparate data. Increasing the ability to share data requires	13.55 Advanced Analytical Techniques for Biologic Drug Discovery: Applying Techniques from Small Molecule Discovery Data diversity, volume and complexity represent challenges	13.55 Using AI to support generation of RWE Chris Boone, Vice President, Real World Data and Analytics, Pfizer	13.55 	13.55 

28th-29th November, 2018
Basel Congress Center

rationalizing and connecting these systems. • IT-enabled portfolio management allows data-driven decisions to be made quickly and seamlessly. • Responsive, agile, and flexible platform that can leverage a cloud based approach Tapan Mehta, Head, Global Healthcare & Life Sciences Marketing, Nutanix	for biologics drug discovery • Small molecule discovery utilizes advanced analytical techniques such as QSAR, matched-molecular pairs, etc., to predict relationships between structure and activity • This talk will discuss adaptation of these techniques to biologics discovery, highlighting successes and potential pitfalls Andrew LeBeau, Senior Manager, Biologics Marketing, Dotmatics			
14.15 Be Data Ready: the story of Sanofi's translational data governance	14.15 Developments Computational medicine	14.15 TERADATA	14.15 Topic TBC Eike Staub	14.15 Liberating evidence from real world data in the

28th-29th November, 2018
Basel Congress Center

• What is data governance ? • Understanding your data ecosystem: key drivers and enablers • The 'How to' implementation challenge: a mix of top-down and bottom-up approaches • Future vision and perspectives Lucie Eckenberg-Friedlander, Translational Medicine Data Governance Leader, Sanofi	Shameer Khader, Program Director (Healthcare Data Science and Bioinformatics), Northwell Health		Director, Head of Oncology Bioinformatics Biopharma R&D Global Early Development, Merck KGaA	21st Century: what have we learned from IMI EMIF, and where will IMI EHDEN take us? • Insights from the IMI European Medical Information Framework project 2013-2018 • What is proposed for the IMI European Health Data and Evidence Network 2018-2023 • Building sustainable infrastructure via federated networks, common data
---	--	--	---	---

28th-29th November, 2018
Basel Congress Center

				models and data ecosystems Nigel Hughes , Scientific Director, Janssen Clinical Innovation, Janssen
14.35 Refreshment Break				
<u>IT, DATA MANAGEMENT AND STORAGE</u>	<u>BIOINFORMATICS</u>	<u>AI AND MACHINE LEARNING</u>	<u>BIG DATA IN ONCOLOGY</u>	<u>DATA INTEGRATION & INFRASTRUCTURE</u>
15.15 Chair's remarks	15.15 Chair's remarks	15.15 Chair's remarks Steve Guise , CIO, Roche	15.15 Chair's remarks	15.15 Chair's remarks Derek Marren , Director - Research IT - Biology systems & Data Integration, Eli Lilly
15.20 Best practices to developing genomic data lakes: Experiences from the Mayo Clinic	15.20 The use of RWD and machine learning in reverse translation •Reverse translation is gaining more importance in drug discovery to support	15.20 Real-world data integration: a Roche story Etzard Stolte , Global Head of Knowledge Management PTD, Roche	15.20 Epigenetics in Cancer Zdenko Herceg , Head, Section of Mechanisms of Carcinogenesis, WHO	15.20 Towards FAIR data: ELIXIR Serena Scollen , Head of Human Genomics and

28th-29th November, 2018
Basel Congress Center

Steven Hart, Associate Director of Bioinformatics, Clinical Genome Sequencing Laboratory (CGSL), Mayo Clinic	application of human data for target-indication prioritization and patient selection •Real world data can provide additional source of information to help selecting the right target for the right indication •Machine learning applied to real world data can provide enhanced characterization of diseases and patient trajectories supporting more robust reverse translation Sandor Szalma, Senior Director, Biomedical Informatics, Takeda Pharmaceuticals			Translational Data, ELIXIR
15. 40 Industrial internet platforms and applications for life sciences Dirk Voelkel, Chief Technology Officer, GE Healthcare	15. 40 Role of AI in bioinformatics and Drug Discovery • Is AI/ML transforming bioinformatics? • Do we have the right data? • Examples of using Advanced Analytics	15. 40 The role of automation in clinical operations Joachim Luithle, Head of Clinical Development Operations, Bayer	15. 40 A look at the HARMONY Alliance: the role of big data for hematology Michel Van Speybroeck, Director Data Sciences, Janssen	15. 40 Developing the AZ Data Architecture Justin Lecher, Scientific Computing/Cloud Computing/HPC

28th-29th November, 2018
Basel Congress Center

	Philippe Sanseau , Head Computational Biology and Stats, GSK			Architect, AstraZeneca
16.00 NTT DATA	16.00 databiology	16.00 ORACLE®	16.00 WuXiNextCODE	16.00 ONTOFORCE
16.20 Cross Pharma HPC Collaboration to Improve Pharma Research and Scientific Outcomes - A decade of successful pre-competitive xPharma HPC collaboration http://www.hpcxpharma.org/ - Classic HPC platforms for R&D - Future-ready data and HPC platforms for clinical and commercial Big Data Mining Zheng Yang , Global Head of Technology and Data Innovation, Customer Value, Boehringer Ingelheim	16.20 Driving value into immunotherapy through AI based response prediction Olivier Elemento , Director, Englander Institute for Precision Medicine	16.20 The Benefits of Bayesian AI - Real-world AI systems need to account for uncertainty and reason probabilistically - Bayesian methods provide a principled approach to dealing with uncertainty - Recent developments in this area will be discussed	16.20 DataBox Project- How to empower patients with their own data and adhere to GDPR Christof Von Kalle , Professor Division of Translational Oncology, N.C.T. and D.K.F.Z.	16.20 Six simple steps to achieve data integration Alexander Krupp , Head of Computational Life Science IT Pharmaceuticals, Bayer

28th-29th November, 2018
Basel Congress Center

		Stanley Lazic , Associate Director, Statistics and Machine Learning, AstraZeneca		
16.40 Refreshment Break (drinks to be served)				
<u>IT, DATA MANAGEMENT AND STORAGE</u>	<u>BIOINFORMATICS & GENOMIC TOOLS</u>	<u>AI, AUTOMATION AND MACHINE LEARNING</u>	<u>BIG DATA IN ONCOLOGY</u>	<u>BIG DATA IN RARE DISEASES</u> Chair: Diego Ardigo , Global Head of Rare Diseases, Chiesi
17.05 Putting data to work in drug discovery - building an AI-enhanced future Ian Barrett , Associate Director, Quantitative Biology, AstraZeneca	17.05 Insights from MedImmune: Tertiary analysis of genomics data David Fenstermacher , Vice President R&D Bioinformatics, MedImmune	17.05 How digital technologies enable precision medicine Martin Erkens , Head of Pharma Research and Early Development Informatics, Roche	17.05 The digital Clinical Trial – potential future hybrid trial models - Digital Clinical Trial Models - Current digitalECMT work	17.05 Predictive modeling for rare diseases Mathew Pletcher , Head of Rare Diseases, Roche

28th-29th November, 2018

Basel Congress Center

			Examples of a range of trail types Dónal Landers, Director - digital Experimental Cancer Medicine Team, CRUK Manchester Institute/The Christie, Senior Director Physician, AstraZeneca	
17.25 Simplifying data analysis and workflow management for life science work flows With advances in DNA sequencing and other research instruments driving unprecedented data growth, terabytes of storage are no longer enough. Wolfgang Mertz, CTO, DELL EMC	17.25 	17.25 	17.25  17.25 PerkinElmer	17.25 

28th-29th November, 2018
Basel Congress Center

				
17.45 Ensuring patient centricity within the digital world - Keeping data focussed on unmet patient need. - Using digital channels to engage HCPs - Gathering patient insights for strategic decisions Tim Cave , VP, Medical Affairs Strategic Planning & Digital Practices, GSK	17.45 Bioinformatics as a Service: A National Resource to Support Biomedical Research in Qatar Mohamed-Ramzi Temanni , Technical Manager – Bioinformatics, SIDRA Medicine	17.45 Lab Data Automation - establishing an automation layer for transferring and exchanging lab data Ralph Haffner , Global Head Discovery Workflows - pRED Informatics, Roche	17.45 Big Data and EHR Defining the Curie Xose Fernandez , Chief Data Officer, Institut Curie	17.45 Presentation Available
18.05 Integrating health into your digital life As Healthcare providers, we need to recognize that people who use our services already have a footprint in the digital world, with services, devices and applications which they are comfortable using. Instituting change in this is likely to lead to	18.05 Massively parallel single-cell CRISPR sequencing in organoid models Genetic epidemiology and CRISPR screens both still struggle to make highly predictive comments about drug target modifiers (i.e. precision medicine).	18.05 	18.05 Computational approaches to I/O in drug development at AstraZeneca Ben Sidders , Team Leader, Oncology Bioinformatics, AstraZeneca	18.05 The rare Disease play book- Developing an Orphan Disease Knowledge Base at Alexion John Reynders , Vice President, R&D Strategy, Program Management and

28th-29th November, 2018
Basel Congress Center

disengaged users, with fewer beneficial outcomes. - The last 20 years have brought with them a tremendous pace of innovation in many industries, and created whole new industries through technology itself. In many cases, these changes have instilled behavior shifts and expectations in users - it is important as healthcare revolutionizes itself to learn from these, to not reinvent the wheel, and accelerate our movement by exploiting benefits and opportunities from other industries. - Obtaining meaningful insight on patients is based on a simple reward/effort ratio. In order to minimize the effort of data collection, this must be seamless, transparent and simple from the person's perspective – integrating with	- Using liver organoid models, while integrating single-cell sequencing with CRISPR, we are dissecting out the cross-talk between metabolic pathways to understand target interactions. - The pipeline and novel methods underlying such genetic screens and the types of results being generated will be presented. Quin Wills, Head of Advanced Genomics, Novo Nordisk			Data Sciences, Alexion Pharmaceuticals Sebastien Lefebvre, Senior Director Data Analytics & Decision Support, Alexion Pharmaceuticals
--	--	--	--	--

28th-29th November, 2018
Basel Congress Center

passive monitoring systems and zero-UI systems make data collection easy, while the value of providing actionable, timely and relevant insight to a patient will keep them engaged with the platform and feel like it provides them with value. David Whewell, Director of Architecture and Software Innovation, Merck Group				
18.25 Close of Conference				

Day 2 – Thursday 29th November 2018

8.55 **Chair's opening remarks**

Morning Plenary

09.00 **Transforming R&D productivity: How can we better turn science into medicine?**

- The future treatment for many of today's diseases lies in discovering new biology to develop novel therapies. The advent of the genomics revolution brings with it an expanding list of pathways and targets to pursue – and with it, new drug discovery challenges

28th-29th November, 2018
Basel Congress Center

- Validating drug targets by understanding and challenging scientific hypotheses has never been more important
- Combining new technologies, focusing on medical understanding, challenging scientific hypotheses and driving strategic partnerships, we are making real progress in our ability to define and prosecute innovative treatment approaches for a variety of complex diseases

Menelas Pangalos, Executive Vice President of Innovative Medicines and Early Development Biotech Unit and Global Business Development, **AstraZeneca**

09.20 **Sponsor keynote**

09:40 **New plans for digital transformation across the NHS**

Harpreet Sood, Chief Clinical Information Officer, Lead NHS Digital Academy and Global Digital Exemplar Program, **NHS England**

Indra Joshi, Head Digital Health and AI Clinical Lead, **NHS**

10.00 **Day One Initiative**

10.20 **Morning refreshments**

<u>ANALYTICS PLATFORMS AND DATA SETS</u>	<u>NEXT GEN SEQUENCING</u>	<u>AI, AUTOMATION AND MACHINE LEARNING</u>	<u>DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS</u>	<u>ROCHE CURATED SESSION</u>
				

28th-29th November, 2018
Basel Congress Center

11.00 Chair's remarks William Paiva , Executive Director, Center for Health Systems Innovation, Oklahoma State University	11.00 Chair's remarks	11.00 Chair's remarks Florian Lipsmeier , Principal Data Scientist; pRED Informatics, Roche	11.00 Chair's remarks Serena Scollen , Head of Human Genomics and Translational Data, ELIXIR	11.00 Chair's remarks
11.05 Using analytics tools to leverage data Mark Baillie , Associate Director, Statistical methodology and consulting, Novartis	11.05 Lab of the future: automated and autonomous lab Darryl Davis , Head of Biophysical Research & Analytics, Janssen	11.05 Machine learning models for ADME optimisation Govinda Rao Bhisetti , Principal Investigator and Head of Computational Chemistry, Biogen	11.05 Leveraging Genetics, Genomics and Proteomics for Translational Research Philippe Marc , Global Head of Integrated Data Sciences, Novartis Institutes for BioMedical Research (NIBR)	11.05 Roche Presentation
11.25 	11.25  OR 	11.25 	11.25 	11.25 Sponsor Presentation
11.45 Machine Learning meets the Human Genome Slavé Petrovski , VP and Head of Genome Analytics, AstraZeneca	11.45 A comprehensive analysis of a RNA-seq dataset at the gene-, isoform- and exon-	11.45 Presentation Available	11.45 Use case: Federated EHR research technology to support clinical trial protocol optimisation:	11.45 Roche Presentation

28th-29th November, 2018
Basel Congress Center

	levels to discover disease progressive biomarkers during diabetic nephropathy • Introduction to ZSF1, a preclinical model for type 2 diabetic nephropathy • Why RNA-seq data should be additionally analyzed at the isoform and exon levels Shanrong Zhao, Director, Computational Biology and Bioinformatics, Pfizer Worldwide Research & Development		Evidence from EHR4CR and the InSite platform • The new federated EHR technology approach – the case of EHR4CR project and deployment program in Europe • Utilise a combination of data sources to effectively structure your developmental strategy • Outlook on performing Pragmatic Clinical Trials & Conclusions Mats Sundgren, Director Health Informatics, AstraZeneca	
12.05				

28th-29th November, 2018
Basel Congress Center

Roundtables 1: AI in Longevity

Dmitry Kaminskiy, Co-founder, Senior Partner, **Deep Knowledge Ventures**

+

Roundtable 2: Patient advocacy within clinical trials

Mimi Choon-Quinones, Executive Senior Director, Clinical Operations and Patient Engagement, **Arena Pharmaceuticals**

+

Round table 3: GDPR

Greg Lefebvre, Genomic Data Science Team Lead, **Nestle Institute of Health Sciences**

Jerome Carayol, Data Analyst, **Nestle Institute of Health Sciences**

Armand Valsesia, Project Lead and Senior Specialist in Statistical Genetics, **Nestle Institute of Health Sciences**

Alix (Leboucq) Zollinger, Genomics Data Analyst, **Nestle Institute of Health Sciences**

+

Round table 4: Analytics for Regulatory and Safety RWE and Epidemiology

Andrew Bate, Senior Director, Analytics Team Lead, Epidemiology, **Pfizer**

+

Round table 5: Digital Endpoints and Validation

John Batchelor, Senior Outcomes Measurement Scientist, **Roche**

Ieuan Clay, Group Lead Digital Endpoints, **Novartis**

+

Round Table 6: Aging and Health

CHAIR Tina Woods, CEO, **Collider Health**

Nastasia Georgievskaya, General Manager, **Youth Laboratories**

Alexander Zhebrak, CTO, **Insilco Medicine**

Kristen Fortney, CEO, **BIOAGE**

Raj Dattani, Principle, **Juvenescence**

28th-29th November, 2018
Basel Congress Center

+

Round Table 7:



+

Round Table 8: Diagnostics & Data

CHAIR: John Reynders, Vice President, R&D Strategy, Program Management and Data Sciences, **Alexion Pharmaceuticals**

Sebastien Lefebvre, Senior Director Data Analytics & Decision Support, **Alexion Pharmaceuticals**

+

Round Table 9: Human Protein Atlas: Big data for human biology and precision medicine

CHAIR: Cecilia Lindskog, Director, **Human Protein Atlas**

+

Round Table 10



+

Round Table 11: Digital Substudies- Big Data in Drug Discovery

Lena Granovsky, Director, Analytics and Big Data, **Teva Pharmaceuticals**

+

Round Table 12: Applied Health Science Research to Improve Clinical Outcomes

Daniel Zahnd, Professor, **Bern University of Applied Science**

+

Round Table 13: Decentralized Trial Settings

Scott Askin, Digital Solutions Director, Digital Development, Portfolio, Strategy & Innovation (PS&I), **Novartis**

+

Round Table 14: Empowering the Person in a Health System: Evidence for Effectiveness

28th-29th November, 2018
Basel Congress Center

Indra Joshi, Head Digital Health and AI Clinical Lead, NHS + Round Table 15: Datalake architecture for R&D Dave Ficenec, Global Head of Architecture, R&D IS/IT, Takeda Pharmaceuticals + Round Table 16: Developing data sharing across the Wellcome Trust Nicola Perrin, Head, Data for Science and Health priority (development phase), Wellcome Trust				
13.00 Networking Lunch				
<u>ANALYTICS & CLOUD PLATFORMS</u>	<u>NEXT GEN SEQUENCING</u>	<u>AI, AUTOMATION AND MACHINE LEARNING</u>	<u>DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS</u>	<u>PRECISION MEDICINE</u>
14.05 Chair's remarks William Paiva, Executive Director, Center for Health Systems Innovation, Oklahoma State University	14.05 Chair's remarks	14.05 Chairs remarks Lena Granovsky, Director, Analytics and Big Data, Teva Pharmaceuticals	14.05 Chair's remarks Mimi Choon-Quinones, Executive Senior Director, Clinical Operations and Patient Engagement, Arena Pharmaceuticals	14.05 Chair's remarks Armand Valsesia, Project Lead and Senior Specialist in Statistical Genetics, Nestle
14.10 Integrating Big Data, Advanced Analytics, Blockchain and IoT Ian Pepper, CTO, Head Strategy and Integration Architecture, Novartis	14.10 Different whole genome sequencing strategies to study HPVs role in cancer development.	14:10 Deep learning and end points Florian Lipsmeier, Principal Data Scientist; pRED Informatics, Roche	14.10 Application of ML to lupus nephritis and extrarenal lupus clinical dataset - lesson learned and main takeaways	14.10 The Swiss personalised healthcare network Torsten Schwede, Director of Data Coordination Centre of the Swiss Personalized Health

28th-29th November, 2018
Basel Congress Center

	• How HPV is involved in the development of different cancers • Strengths and weaknesses of different whole genome sequencing strategies to study HPV integrations in cancer • Time vs Money where should you invest? David Smith, Professor of Laboratory Medicine and Pathology, Mayo Clinic		• We adapted Eureka software (Nutonian) to screen baseline and time-varying clinical and laboratory parameters for associations with outcome using pooled data from recent trials in lupus nephritis (LN) and extrarenal lupus (ERL) • In LN, Eureka confirmed known associations with outcome but also several trivial associations. Eureka did not identify meaningful associations between clinical variables and outcome in ERL trials • Eureka is a potentially exciting tool to assist with discovery of novel associations in clinical data and hypothesis generation	Network, Swiss Institute of Bioinformatics
--	---	--	--	---

28th-29th November, 2018
Basel Congress Center

			Marco Prunotto , Senior Clinical Development Scientist, Roche	
14.30 	14.30 Using AI for drug target discovery • Case studies over the last five years • Precision Medicine based clinical trials • RWE in practice Slava Akmaev, Vice President and Chief Analytics Officer, BERG Health	14.30 	14.30 	14.30 Sponsor presentation
14.50 Decision making platforms and data quality at pRED Jorg Degen, Principal Scientist of Discovery Oncology, Roche	14.50 Omics and pathway analysis for disease understanding in pain • Pain as a disease	14:50 Title to be confirmed Tom Rush, ATOM Chief Scientific Officer & Interim Co-Lead, Senior Director	14.50 Surfing the Tsunami Opportunities and Challenges of Digital in Clinical at Abbvie	14.50 Precision and recall oncology: combining multiple gene alterations for improved identification of drug-sensitive tumours

28th-29th November, 2018
Basel Congress Center

	- Interpretation of Omics data and Pathways - Pain Landscapes and Disease Understanding Achim Kless, Scientific Director, Grunenthal	and Head of Biology Automation, GSK	Rob Scott , VP Development and Chief Medical Officer, AbbVie	Pedro Ballester , Research Group Leader, INSERM
15.10 Afternoon Refreshments				
<u>SOFTWARE & APPLICATIONS</u>	<u>EVIDENCE</u>	<u>AI, AUTOMATION AND MACHINE LEARNING</u>	<u>DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS</u>	<u>PRECISION MEDICINE</u>
15.40 Achieving an integrated approach to software and applications Jan Kuentzer, Head of Data Science Application Services, Roche	15.40 RWE at Novartis- Changing the value proposition Athula Herath, Global Head of Real World Evidence Epidemiology, Novartis	15:40 Federated learning: leveraging the power of private data Federated learning approach allows to build powerfull models from separated datasets	15.40 Modeling and simulation for clinical sciences in the cloud under GPX Jobst Loeffler, Project Manager, Bayer Business Services GmbH, IT Operations, Scientific Development IT, Bayer	15.40 The Genomics of Rare Diseases at Boston Children's Hospital - The importance of phenotyping, transparency, and patient engagement - The delicate balance of data sharing, discovery, and translation to the clinic

28th-29th November, 2018
Basel Congress Center

		- This techniques enables to build efficients models without compromising the privacy of individual datasets - Examples of applications in medicine Mikhail Zaslavskiy, Head of R&D, OWKIN		- Case studies of big data projects at a tertiary children's hospital - Collaborations with Industry to make rare disease discoveries Catherine Brownstein, Scientific Director, Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School
16.00 Sponsor presentation	16.00	16.00 	16.00 Sponsor presentation	16.00 Sponsor presentation
16.20 How to Infuse the Human Perspective to Digital Health?" Most paradigms of the digital health revolution, such as digital therapeutics, precision medicine, outcome-based health	16.20 Accelerating Advances in Cancer Therapy through RWD	16.20 Predicting Cardiac Drug Toxicity through AI-Chemotherapy vs Cardiac toxicity	16.20 Decentralised, Disruptive Digital trials- Utilizing next generation phenotypic sensors Michelle Krishnan ,	16.20 Scaling up trustworthy data access for personalised care and research Real World Evidence decision making and Precision Medicine

28th-29th November, 2018
Basel Congress Center

systems, and self-care are critically dependent on changing behavioural aspects of patients • Impactful digital health initiatives are therefore best co-developed with patients in a human-centric manner • Patients can participate in product and service development at scale through a novel service platform for patient engagement, specifically trained resources, and a network of relevant partners Oliver Gassner, Head Digital Health Intelligence EMEA, Bayer	Jacqueline Law, Vice President, Global Head, PHC Data Science, Personalized Healthcare, Product Development, Genentech	Polina Mamoshina, Research Scientist, Pharma.AI	Translational Medicine Leader in Rare Diseases, Roche	need greater access to big health data: clinical data, genomic biomarkers, wellness and lifestyle. • Trustworthy data sharing is vital to scaling up data access: trust in privacy protection, trust in the quality of the data and trust in how data are used. • Stakeholders and efforts need to collaborate, especially with patients, to develop a portfolio of equitable and acceptable models that can be promoted globally. Dipak Kalra, President of the European Institute for Health Records, President, European
---	---	--	---	---

28th-29th November, 2018
Basel Congress Center

				Institute for Innovation through Health Data
16.40 Chair's Closing Remarks	16.40 Chair's Closing Remarks	16.40 Chair's closing remarks	16.40 Chair's Closing Remarks	16.40 Chair's Closing Remarks

16.45 Close of conference

28th-29th November, 2018
Basel Congress Center

Start-up seminar

Innovation Zone		
Chair: Vikram Bajaj, Managing Director, Forsite Capital Management, Former CSO Grail, Co-Founder, Verily (Google Life Sciences) Vadim Shpak, Managing Director, Vickers Venture Partners Dmitry Kaminskiy, Co-founder, Senior Partner, Deep Knowledge Ventures William Paiva, Executive Director, Center for Health Systems Innovation, OSU, Managing Partner, Oklahoma Life Science Fund Raj Dattani, Principle, Juvenescence		
	Blue Stream	Red Stream
13:00	Janus Genomics Robin Röhm , CEO and Co-Founder, Janus Genomics	Presentation
13:05	ProteinQure Inc Mark Fingerhuth , Founder & CEO, ProteinQure Inc	Harpreet Sood , Chief Clinical Information Officer, NHS England
13:10	Pangea Data Vibhor Gupta , Director and Founder, Pangea Data	Owkin Thomas Clozel , Founder & CEO, Owkin
13:15	Sidekick Health- Reserved TBC	Presentation
13:20	Bright Peak Roberto Iacone , CSO/VP, Bright Peak	Presentation
13:25	OneThree Biotech Neel Madhukar , Runway Startup Postdoc Forbes 30Under30 (Healthcare), Runway Startup Postdoc, Weill Cornell Medicine	Presentation
13:30	SensDX Dawid Nidzworski , CTO, SensDX	Presentation
13:35	Solvuu TBC Raj Sasidharan , Director of Genomics, Solvuu	Presentation
13:40	Chronomics Tom Stubbs , CEO, Chronomics	Presentation
13:45	Nutrigenomics the business case Greg Lefebvre , Genomic Data Science Team Lead, Nestle Institute of Health Sciences	Presentation
13:50	Q&A	Q&A
13:55		

28th-29th November, 2018
Basel Congress Center

Datathon

DATATHON ON OPEN TARGETS: In partnership with EMBL- EBI, GSK and NASA Genlab

Part 1: Educating on the open targets platform

Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.

Visit the [Open Targets Platform](#) which provides an integration of public domain data to enable target identification and prioritisation.

Generating and interpreting the data required to identify a good drug target demands a diverse set of skills, backgrounds, evidence types and technologies, which do not exist today in any single entity. Open Targets brings together expertise from four complementary institutions to systematically identify and prioritise targets from which safe and effective medicines can be developed.

Our goals are to:

- Systematically find the best targets to safely & effectively treat disease
- Help others find good targets
- Get those targets adopted into drug discovery pipelines

We currently focus on oncology, immunology and neurodegeneration through an R&D framework that can be applied to all aspects of human disease

Instructors and Leaders:

Ian Dunham, Scientific Director, Open Targets, **EMBL-EBI**

Matthew Nelson, Head of Genetics, **GSK**

Mark Hurle, Director of Computational Biology, **GSK**

Gautier Koscielny, Scientific Director, Open Targets, **GSK**